Home Newsfeeds JP Morgan Maintains Neutral on Alkermes, Lowers Price Target to $29

JP Morgan Maintains Neutral on Alkermes, Lowers Price Target to $29

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and lowers the price target from $33 to $29.

byBenzinga Newsdesk

December 6, 2022

1 minute read

JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and lowers the price target from $33 to $29.

Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline

By Vandana Singh

February 1, 8:42 AM

Amgen Inc’s (NASDAQ:AMGN) fourth-quarter revenues were $6.84 billion, beating the consensus of $6.76 billion, largely unchanged from Q4 2021, and…

ABBV

Why Is European Healthcare Tech Giant Philips Stock Trading Higher On Wednesday?

By Vandana Singh

April 10, 9:47 AM

Philips has finalized an agreement with US authorities and the FDA regarding the recall of Respironics ventilators. Consent decree mandates remediation prioritization and operational focus in the US. Business outlook and financial guidance remain stable.

PHG

Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie’s $100M Pledge Update

By Lara Goldstein

September 18, 3:10 PM

Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).

ATAI